Trump Faces Uphill Battle Seeking China’s Help on Iran Conflict 
Trump Says Iran Ceasefire ‘On Life Support’ as Oil Prices Surge Above $104 
Trump Pushes China Market Access During High-Stakes Xi Summit 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Trump and Xi Temple of Heaven Visit Highlights Trade and Diplomacy Goals 
Honda Annual Loss Deepens as U.S. Tariffs and EV Costs Weigh on Earnings 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
OpenAI Finds No Evidence of User Data Breach in TanStack npm Supply-Chain Attack 
Japan Considers Extra Budget Aid Amid Rising Fuel and Utility Costs 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
OECD Sees Bank of Japan Raising Interest Rates to 2% by 2027 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
SK Hynix Nears $1 Trillion Market Value Amid South Korea’s AI-Driven Stock Market Surge 
Dulles Airport Rebuild Plan Could Transform Washington’s Main International Gateway 
Asian Currencies Slide as Indian Rupee Hits Record Low Amid Iran Tensions 
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
